One of the diabetes market’s newest spinoffs is set to undergo a significant change. Embecta, which was spun out of Becton Dickinson in April of 2022, is instituting a restructuring plan that includes ...

PARSIPPANY, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced it has ...

Devdatt (Dev) Kurdikar, CEO of Embecta (EMBC) said, “As our stand-up work nears completion and following an in-depth review of our portfolio and strategy, we have decided to discontinue our insulin ...

PARSIPPANY, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced its ...

Embecta Corp., a global diabetes care company, recently announced it has received 510(k) clearance from the U.S. Food and Drug Administration for its disposable insulin delivery system. Indicated for ...

Embecta Corp (NASDAQ:EMBC), a manufacturer of disposable insulin pen needles and syringes, is considering a potential sale following a significant drop in its share price since being spun off from ...

While 9 out of 10 people with diabetes are living with T2D, many of the automated insulin delivery solutions currently on the market were designed for people living with T1D. 300-unit insulin ...